Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed 4-1BB-CD3ζ CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas

X
Trial Profile

Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed 4-1BB-CD3ζ CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glofitamab (Primary) ; Mosunetuzumab (Primary) ; Obinutuzumab (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 May 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 14 Dec 2021 Status changed from not yet recruiting to recruiting.
    • 11 Oct 2021 Planned initiation date changed from 15 Aug 2021 to 1 Nov 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top